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Abstract
Background: Protein kinase D (PKD) has been implicated in a wide range of cellular processes and pathological 
conditions including cancer. However, targeting PKD therapeutically and dissecting PKD-mediated cellular responses 
remains difficult due to lack of a potent and selective inhibitor. Previously, we identified a novel pan-PKD inhibitor, 
CID755673, with potency in the upper nanomolar range and high selectivity for PKD. In an effort to further enhance its 
selectivity and potency for potential in vivo application, small molecule analogs of CID755673 were generated by 
modifying both the core structure and side-chains.
Results: After initial activity screening, five analogs with equal or greater potencies as CID755673 were chosen for 
further analysis: kb-NB142-70, kb-NB165-09, kb-NB165-31, kb-NB165-92, and kb-NB184-02. Our data showed that 
modifications to the aromatic core structure in particular significantly increased potency while retaining high 
specificity for PKD. When tested in prostate cancer cells, all compounds inhibited PMA-induced autophosphorylation 
of PKD1, with kb-NB142-70 being most active. Importantly, these analogs caused a dramatic arrest in cell proliferation 
accompanying elevated cytotoxicity when applied to prostate cancer cells. Cell migration and invasion were also 
inhibited by these analogs with varying potencies that correlated to their cellular activity.
Conclusions: Throughout the battery of experiments, the compounds kb-NB142-70 and kb-NB165-09 emerged as the 
most potent and specific analogs in vitro and in cells. These compounds are undergoing further testing for their 
effectiveness as pharmacological tools for dissecting PKD function and as potential anti-cancer agents in the treatment 
of prostate cancer.
Background
The PKD family is a novel family of serine/threonine
kinases and diacyglycerol (DAG) receptors. Three iso-
forms of PKD have been identified so far: PKD1 (formerly
PKCμ), PKD2, and PKD3 (PKCν) [1-4]. Originally classi-
fied as a member of the protein kinase C (PKC) family,
the PKD family is now recognized as a subfamily of the
calcium/calmodulin-dependent kinase superfamily, and
is only distantly related to PKC in structure [5,6]. All iso-
forms contain a catalytic domain, a cysteine-rich DAG-
binding domain (C1), and a pleckstrin homology (PH)
domain that negatively regulates PKD activity [7]. DAG
regulates the localization of PKD through binding to its
C1 domain [4] and its activity through regulating PKC-
dependent phosphorylation of PKD on serines 738 and
742 (Ser738/742) in the activation loop [8,9]. Rapid, early
activation of PKD by PKC then leads to autophosphoryla-
tion of PKD on serine 916 (Ser916) and subsequent full
activation of PKD [10]. Interestingly, recent evidence sug-
gests that while Ser742 transphosphorylation by PKC is
required for early activation of PKD, Ser742 is also a site of
autophosphorylation, and that autophosphorylation at
this site is required for maintaining prolonged PKD acti-
vation [11].
Since its discovery, PKD has been implicated in various
cellular functions significant to tumor development
including proliferation, survival, apoptosis, angiogenesis,
and motility. For example, PKD activation in response to
vascular endothelial-derived growth factor (VEGF) or
bombesin leads to activation of extracellular signal-regu-
lated kinase (ERK) 1/2, regulating cell proliferation in
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several cell types [12,13]. PKD can also be activated by
oxidative stress, which modulates cell survival through
the NF-κB and JNK signaling pathways [14-16]. Further-
more, PKD has been implicated in the regulation of the
epithelial to mesenchymal transition in prostate cancer
cells by modulation of β-catenin, and angiogenesis in vas-
cular endothelial cells through modulating phosphoryla-
tion and nucleocytoplasmic shuttling of class IIa histone
deacetylases (HDACs) [15,17]. Disruption of these funda-
mental pathways could potentially lead to the develop-
ment, progression, and metastasis of cancer. In recent
studies, PKD expression has been shown to be dysregu-
lated in human prostate cancer tissues [18,19], implicat-
ing a role for PKD in the progression of prostate cancer.
To support this, we previously reported that a knock-
down of PKD3, a member of the PKD family, using
siRNA caused a dramatic arrest in cell proliferation in
PC3 cells [18]. Furthermore, we also found that inhibition
of PKD using the novel PKD inhibitor CID755673 not
only reduced proliferation in LNCaP, DU145, and PC3
cells, but also significantly slowed migration and invasion
of PC3 and DU145 cells [20].
Our previous report identified CID755673 as a potent
and selective PKD inhibitor with an in vitro IC50 for
PKD1 of 182 nM [20]. This compound also was active in
cells and inhibited multiple known biological functions of
PKD. CID755673 was highly selective and did not inhibit
multiple PKC isoforms tested, or CAMKIIα. This
remarkable selectivity represents a significant improve-
ment over compounds previously used to inhibit PKD,
such as Gö6976, a compound known foremost for its
inhibition of PKCs [21]. Despite its apparent high speci-
ficity and potent inhibition of PKD in vitro, its cellular
activity was relatively weak. Efforts to improve the
potency of this compound are imperative to ensure its
effective application in cells and animals.
In this study, we present the in vitro and cellular activity
of five novel analogs of CID755673. The analogs were
synthesized with modifications to both their core struc-
tures and side chains. We show that several of these ana-
logs exhibited increased potency toward PKD inhibition
both in vitro and in cells. Additionally, they cause potent
growth arrest, moderate cell death, and inhibition of
migration and invasion in prostate cancer cells, support-
ing their potential for in vivo applications.
Methods
Chemicals and reagents
DMSO was purchased from Sigma. PKCα was obtained
from Cell Signaling Technology and Calbiochem, PKCβI
was from Cell Signaling Technology, and PKCδ was from
Enzo Life Sciences. Myelin basic protein 4-14 was pur-
chased from Sigma. CID755673 and its analogs, kb-
NB142-70, kb-NB165-09, kb-NB165-31, kb-NB165-92,
and kb-NB184-02, were synthesized according to stan-
dard organic synthesis procedures [22-27].
Synthesis of CID755673
CID755673 and its byproduct CID797718 were synthe-
sized according to Fig. 1 and the following experimental
protocols:
3,3-Dibromoazepan-2-one (1). A solution of ε-capro-
lactam (15.1 g, 0.133 mol) in CHCl3 (400 mL) was cooled
to 0-5°C and PCl5 (55.2 g, 0.265 mol) was added over the
course of 30 min followed by addition of anhydrous ZnI2
(1.53 g, 4.79 mmol) under N2. The reaction mixture was
slowly allowed to reach rt as Br2 (42.4 g, 0.265 mol) was
added dropwise over 30 min. The mixture was stirred at
rt for 6 h and then poured into ice-water (300 mL). The
aqueous layer was separated and extracted with CHCl3 (3
× 100 mL). The combined organic fractions were washed
with 0.50 M aq NaHSO3 (3 × 200 mL) and brine (1 × 400
mL), dried (MgSO4), and concentrated to yield a yellow
solid residue. The solid was suspended in water, filtered,
and washed with water and Et2O to give 1 (27.5 g, 101.5
mmol, 76% yield) as a white solid: mp 161-163°C (lit 162-
164°C);[25]1H NMR (CDCl3, 600 MHz) δ 6.07 (bs, 1 H),
3.38 (dd, J = 10.2, 6.0 Hz, 2 H), 2.75 (t, J = 6.0 Hz, 2 H), 2.0
(quint., J = 6.0 Hz, 2 H), 1.72 (quint., J = 6.0 Hz, 2 H); 13C
NMR (CDCl3, 150 MHz) δ 168.5, 69.5, 45.9, 42.6, 28.4,
28.2; IR (ATR, neat) 3201, 3085, 2940, 2929, 1661, 1464,
1407, 1326 cm-1; HRMS (ES+) m/z calcd for C6H9Br2NO
[M+Na]+, 291.8949, found 291.8973.
3-Piperidin-1-yl-1,5,6,7-tetrahydroazepin-2-one (2). A
solution of 1 (27.0 g, 99.7 mmol) in piperidine (240 mL)
was heated at reflux for 4.5 h under N2. The solution was
allowed to reach rt and washed with 0.50 M aq NaHSO3
(200 mL). The aqueous phase was separated and
extracted with CHCl3  (3 × 100 mL). The combined
organic fractions were washed with brine (1 × 300 mL),
dried (MgSO4), and concentrated to afford a yellow solid,
which was suspended in water, filtered, and washed with
water and Et2O to give 2 (17.6 g, 90.59 mmol, 91% yield)
as a white solid: mp 140-143°C (lit 139-144°C); 1H NMR
(CDCl3, 600 MHz) δ 6.59 (bs, 1 H), 5.06 (t, J = 7.8 Hz, 1
H), 3.22 (dd, J = 13.2, 6.6 Hz, 2 H), 2.78 (t, J = 5.4 Hz, 4 H),
2.15 (dd, J = 14.4, 7.2 Hz, 2 H), 1.76 (quint., J = 6.6 Hz, 2
H), 1.65 (quint., J = 5.4 Hz, 4 H), 1.51 (quint., J = 6.0 Hz, 2
H);  13C NMR (CDCl3, 150 MHz) δ 171.2, 147.3, 105.2,
49.9 (2 C), 39.3, 30.0, 25.3 (2 C), 24.3, 21.3; IR (ATR, neat)
3193, 2950, 2923, 2935, 2855, 1655, 1605 cm-1; HRMS
(EI+)  m/z  calcd for C11H18N2O [M]+, 194.1419, found
194.1422.
7-Hydroxy-10a-piperidino-2,3,4,5,5a,10a-hexahyd-
robenzofuro[2,3-c]azepin-1(1H)-one (3). A mixture ofLaValle et al. BMC Chemical Biology 2010, 10:5
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1,4-benzoquinone (0.568 g, 5.15 mmol) and enamine 2
(1.00 g, 5.15 mmol) in anhydrous EtOH (4 mL) was
stirred for 11 h at rt. The precipitate was filtered off,
washed with absolute EtOH and dried under high vac-
uum to give 3 (1.12 g, 3.704 mmol, 77% yield) as a light
pink solid: mp 254-255°C (lit 257-260°C);[27]1H NMR
(DMSO-d6, 600 MHz) δ 8.73 (s, 1 H), 7.60 (t, J = 7.2 Hz, 1
H), 6.55 (d, J = 1.8 Hz, 1 H), 6.52 (d, J = 9.0 Hz, 1 H), 6.48
(dd, J = 9.0, 2.4 Hz, 1 H), 3.91 - 3.99 (m, 1 H), 3.28 (d, J =
12.6 Hz, 1 H), 2.91 - 2.98 (m, 1 H), 2.60 - 2.66 (m, 2 H),
2.39 - 2.46 (m, 2 H), 1.92 (d, J = 13.8 Hz, 1 H), 1.68 (quint.,
J = 4.5 Hz, 2 H), 1.32 - 1.49 (m, 7 H); 13C NMR (DMSO-
d6, 150 MHz) δ 169.9, 151.3, 151.1, 130.1, 115.0, 111.1,
108.4, 107.4, 47.2, 46.9 (2 C), 38.2, 29.7, 27.1, 26.4 (2 C),
24.8; IR (ATR, neat) 3259 (br), 2949, 2849, 2824, 1649,
1472, 1351, 1208 cm-1; HRMS (EI+)  m/z  calcd for
C17H22N2O3 [M]+, 302.1630, found 302.1625.
7-Hydroxy-2,3,4,5-tetrahydro-[1]benzoxolo[2,3-c]aze-
pin-1-one CID755673 and 9-hydroxy-1,2,3,4-tetrahydro-
chromeno[3,4-b]pyridin-5-one  CID797718. Adduct 3
(2.0 g, 6.61 mmol) was suspended in conc HCl (6 mL) and
the reaction mixture was heated at 100°C for 3 h under
N2. After cooling the solution down to rt, a light amber
precipitate was formed, which was washed with Et2O and
filtered. The solid was dissolved in the minimum amount
of MeOH, preadsorbed on SiO2 and purified by chroma-
tography on SiO2  (5% MeOH in CH2Cl2  to  i-PrOH,
100%), to yield CID755673 (1.19 g, 5.48 mmol, 83% yield)
and  CID797718  (0.118 g, 0.543 mmol, 8% yield).
CID755673: mp (i-PrOH) 245-247°C (lit. 244-
247°C);[27]1H NMR (DMSO-d6, 600 MHz) δ 9.36 (s, 1
H), 8.09 (t, J = 4.8 Hz, 1 H), 7.41 (d, J = 9.0 Hz, 1 H), 6.92
(d, J = 2.4 Hz, 1 H), 6.90 (dd, J = 9.0, 2.4 Hz, 1 H), 3.24 (dd,
J = 9, 4.8 Hz, 2 H), 2.89 (t, J = 6.6 Hz, 2 H), 1.98 - 2.02 (m,
2 H); 13C NMR (DMSO-d6, 150 MHz) δ 161.9, 153.9,
148.1, 144.3, 129.6, 123.5, 116.9, 112.4, 105.1, 41.2, 26.8,
24.3; IR (ATR, neat) 3187 (br), 3059, 2921, 1680, 1579,
1472, 1435, 1339, 1166 cm-1; HRMS (ES+) m/z calcd for
C12H11NO3  [M+H]+, 218.0817, found 218.0832;
CID797718:  mp (i-PrOH) 217-218°C (lit. 213-
216°C);[27]1H NMR (DMSO-d6, 600 MHz) δ 9.41 (s, 1
H), 7.09 (d, J = 9.0 Hz, 1 H), 6.74 (d, J = 3.0 Hz, 1 H), 6.66
(dd, J = 9.0, 3.0 Hz, 1 H), 5.91 (s, 1 H), 3.22 - 3.24 (m, 2 H),
2.59 (t, J = 6.6 Hz, 2 H), 1.85 - 1.90 (m, 2 H); 13C NMR
(DMSO-d6, 150 MHz) δ 158.1, 154.5, 140.9, 129.8, 122.9,
116.8, 114.8, 113.4, 106.4, 40.3, 21.6, 20.6; IR (ATR, neat)
3401, 3305 (br), 2937, 2879, 1662, 1583, 1449, 1342, 1219,
1184 cm-1; HRMS (ES+)  m/z  calcd for C12H11NO3
[M+H]+, 218.0817, found 218.0802.
In Vitro Radiometric PKD or CAMK Kinase Assay
In vitro radiometric kinase assays were conducted as pre-
viously described [20]. Briefly, 1 μCi [γ-32P] ATP (Perki-
nElmer Life Sciences), 70 μM ATP, 50 ng purified
recombinant human PKD1 (Biomol International, Plym-
outh Meeting, PA), PKD2 (SignalChem, Richmond, BC,
Canada), or CAMKIIα (Enzo Life Sciences) or 75 ng
PKD3 (Enzo Life Sciences), and 2.5 μg syntide-2 (Sigma)
in 50 μl kinase buffer containing 50 mM Tris-HCl, pH
7.5, 4 mM MgCl2, and 10 mM β-mercaptoethanol. For the
CAMK assay, 0.5 mM CaCl2 and 30 ng/μl calmodulin
were pre-incubated for 10 min on ice, and then added to
Figure 1 Synthesis and chemical structures of CID755673 and CID797718. CID755673, a compound identified and confirmed as a PKD1 inhibitor 
after interrogation of the PMLSC library, and CID797718, an analog of CID755673 obtained during the synthesis of the latter structure, were synthe-
sized as described in "Methods".LaValle et al. BMC Chemical Biology 2010, 10:5
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each reaction mixture. The reaction was incubated at
30°C for 10 min, and 25 μl of the reaction mixture was
then spotted onto Whatman P81 filter paper (Whatman
Inc., Clifton, NJ). The filter papers were washed 3 times
in 0.5% phosphoric acid, air-dried, and counted using a
Beckman LS6500 multipurpose scintillation counter
(Beckman).
In Vitro Radiometric PKC Kinase Assay
The PKC in vitro kinase assays were performed as
described previously [20].
Cell Lines and Western Blot Analysis
DU145 and PC3 cells were maintained in RPMI 1640 sup-
plemented with 10% fetal bovine serum (FBS) and 1000
units/l penicillin, and 1 mg/ml streptomycin in 5% CO2 at
37°C. LNCaP cells were maintained as described previ-
ously [18]. Western blot analysis was carried out as previ-
ously reported [28]. Briefly, cells were lysed in lysis buffer
containing 200 mM Tris-HCl, pH 7.4, 100 μM 4-(2-amin-
oethyl) benzenesulfonyl fluoride, 1 mM EGTA, and 1%
Triton X-100. Protein concentration was determined
using the BCA Protein Concentration Assay reagent kit
(Pierce) and then equal amounts of protein were sub-
jected to SDS-PAGE followed by electrotransfer to nitro-
cellulose membranes. Membranes were blocked with 5%
nonfat milk in Tris-buffered saline and then probed with
primary antibodies for either p-S916-PKD1 (Millipore),
p-S742-PKCμ/PKD (Biosource), or GAPDH, followed by
anti-mouse or anti-rabbit secondary antibodies conju-
gated to horseradish peroxidase (Bio-Rad). The enhanced
chemiluminescence (ECL) Western blotting detection
system (Amersham Biosciences) was used to facilitate
detection of protein bands.
MTT Assay
PC3 cells were seeded into 96-well plates (3000 cells/well)
and allowed to attach overnight. Cells were then incu-
bated in media containing 0.3-100 μM inhibitors for 72 h.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide methyl thiazolyl tetrazolium (MTT) solution
was prepared at 2 mg/ml concentration in PBS, sterilized
by filtering through a 0.2 μm filter, and wrapped in foil to
protect from light. 50 μl MTT solution was added to each
well and incubated for 4 h at 37°C. Then, media was
removed and 200 μl DMSO was added to each well. The
Figure 2 Chemical structures and SAR of CID755673 and its analogs. A, Diagram describing the major structural zones dissected for SAR analysis. 
B, Chemical structures of the parental compound CID755673, previously identified and confirmed as a pan-PKD inhibitor, and of five analogs of 
CID755673.
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plate was mixed for 5 min and the optical density was
determined at 570 nm.
Cell Proliferation Assay and Cell Cycle Analysis
Proliferation of PC3 cells was measured by counting the
number of viable cells upon trypan blue staining as previ-
ously described [18]. Cell cycle analysis was performed as
described [18]. Briefly, PC3 cells were treated with indi-
cated compounds at 10 μM concentration for 48 h, and
then fixed in 70% ice-cold ethanol overnight and labeled
with propidium iodide. The labeled cells were analyzed
using a FACScan Benchtop Cytometer (BD Biosciences).
Wound Healing Assay
Wound-induced migration was measured as described
previously [20]. Briefly, PC3 or DU145 cells were grown
to confluence in 6-well plates. Migration was initiated by
scraping the monolayer with a pipette tip, creating a
"wound." The indicated concentration of compound was
added to the media, and the wound was imaged immedi-
ately under an inverted phase-contrast microscope with
10× objective. After 24 h, cells were fixed in methanol
and stained with 1% crystal violet, and a final image was
taken. The wound gap was measured, and % wound heal-
ing was calculated. The average % wound healing was
determined based on at least 9 measurements of the
wound gap.
Matrigel Invasion Assay
DU145 cells (8.0 × 104 cells/ml) in RPMI containing 0.1%
fetal bovine serum (FBS) were seeded into the top cham-
ber of BioCoat control inserts (pore size 8 μm) or BioCoat
Matrigel invasion inserts with Matrigel-coated filters (BD
Pharmingen). To stimulate invasion, media in the lower
chamber of the insert contained 20% FBS. Inhibitors were
added at 10 μM concentration to both the upper and
lower chambers, and cells were incubated for 22 h. After
incubation, noninvasive cells were removed using a cot-
ton swab, and invasive cells were fixed in 100% methanol
and stained with 1% crystal violet. After staining, cells
were counted under a microscope (200× magnification).
The percentage invasion was determined by cell counts in
5 fields of the number of cells that invaded the Matrigel
matrix relative to the number of cells that migrated
through the control insert.
Statistical Analysis
Statistical analysis was completed using GraphPad Prism
V software. A p value of < 0.05 was considered statisti-
cally significant.
Results
Design of CID755673 analogs
CID755673 and CID797718, a structural analog of
CID755673, were synthesized by the PMLSC Chemistry
Core following the scheme illustrated in Fig. 1 (see
Figure 3 Inhibition of PKD by CID755673 analogs in vitro. A-E, inhibition of recombinant human PKD1 in vitro. PKD kinase activity was assayed by 
a radiometric kinase assay in the presence of increasing concentrations of the CID755673 analogs. A 10-point concentration curve was generated for 
each compound for IC50 determination. Each IC50 was determined as the mean ± S.E.M. of three independent experiments with triplicate determina-
tions at each concentration in each experiment. Representative graphs are shown.LaValle et al. BMC Chemical Biology 2010, 10:5
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"Methods" for details of the synthesis). CID797718 is a
byproduct of CID755673 synthesis, and has 10-fold less
inhibitory activity toward PKD than the parental com-
pound [20].
The design of the CID755673 analogs was based on ini-
tial structure-activity relationship (SAR) analysis
described in a separate manuscript (Bravo-Altamirano K,
LaValle CR, Byerly R, Giridhar KV, Chen J, Leimgruber S,
Barrett R, Sharlow ER, Lazo JS, Wang QJ, Wipf P. Synthe-
sis and Structure-Activity Relationship Evaluation of
Selective Small-Molecule Inhibitors for Protein Kinase D,
manuscript submitted). We dissected the parent com-
pound CID755673 into 4 major structural zones in order
to elucidate a fundamental SAR (Fig. 2A). In zone I, we
modified the phenolic substituent as well as the α-posi-
tion on the aromatic ring. In zone II, we substituted the
oxygen ring atom with sulfur and nitrogen. In zone III, we
altered the ring size by adding or removing methylene
groups, as well as substituting the benzylic position. In
zone IV, we pursued functional group interconversions as
well as replacement of the amide with heterocyclic
groups. Most of the zone I derivatives were considerably
less active than CID755673 in the PKD screen. In particu-
lar, carbon substituents ortho to the phenol and O-benzy-
lations were detrimental. In contrast, ortho-halogenation
and O-methylation were well tolerated. Nitrogen replace-
ments in zone II were associated with loss of activity,
whereas sulfur substitution was not only tolerated well
but lead often to a substantial increase in activity. Among
the zone III substitutions, a thioether insertion exo to the
five-membered heterocycle and an additional methylene
group (leading to an eight-membered fused ring) were
well tolerated. Finally, all zone IV substitutions were
unsatisfactory, and we decided to retain the amide func-
tion of CID755673 in this position.
Figure 4 Inhibition of PMA-induced endogenous PKD1 activation in LNCaP cells. LNCaP cells were pretreated with indicated concentrations of 
the five analogs for 45 min, then stimulated with 100 nM PMA for 20 min. Cell lysates were immunoblotted for p-S916-PKD1 and p-S742-PKD1. GAPDH 
was blotted as a loading control. The experiment was repeated at least three times and representative blots are shown.
Table 1: In vitro inhibitory activity of CID755673 and its analogs for PKD
IC50 (nM)
Compound PKD1 PKD2 PKD3
CID755673 182 ± 27 (n = 5) 280 ± 1.8 (n = 3) 227 ± 24 (n = 3)
Kb-NB142-70 28.3 ± 2.3 (n = 3) 58.7 ± 4.2 (n = 3) 53.2 ± 3.5 (n = 3)
Kb-NB165-09 82.5 ± 4.6 (n = 4) 141.6 ± 7.4 (n = 3) 98.5 ± 15.3 (n = 3)
Kb-NB165-31 114.1 ± 23.9 (n = 3) 162.9 ± 20.5 (n = 3) 91.1 ± 17.2 (n = 3)
Kb-NB165-92 111.2 ± 6 (n = 3) 100.7 ± 10.9 (n = 3) 58.8 ± 7.3 (n = 3)
Kb-NB184-02 192.8 ± 27.4 (n = 3) 463.2 ± 38.2 (n = 4) 324.7 ± 39.0 (n = 3)
IC50 were determined for CID755673 and its analogs against PKD1, -2, and -3 using radiometric kinase activity assays. Each IC50 was calculated 
as the mean ± S.E.M. of at least three independent experiments with triplicate determinations at each concentration in each experiment as 
described in "Methods." *n, number of independent experimentsLaValle et al. BMC Chemical Biology 2010, 10:5
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After initial screening and the SAR analysis on ca 50
analogs summarized above, five novel compounds with
equal or greater potency for PKD were selected for fur-
ther testing (Fig. 2B).
In vitro activities of CID755673 analogs
The in vitro inhibitory activities of the novel compounds
toward PKD were determined using radiometric PKD
kinase activity assays. Recombinant human PKD1, -2, or -
3 was incubated with the substrate, syntide-2, in the pres-
ence of 10 different concentrations of each compound.
IC50 values were determined for each compound by plot-
ting percent PKD activity versus compound concentra-
tion for each point. We found that while the compounds
inhibited all three PKD isoforms, their potency and selec-
tivity varied (Fig. 3A-E and Table 1). The most potent
compound was found to be kb-NB142-70, which inhib-
ited PKD1 with an IC50 of 28.3 ± 2.3 nM (n = 3), showing
a 7-fold greater inhibition than the parental compound
(Table 1). This compound was also a robust inhibitor of
PKD2 and -3, demonstrating respective IC50s of 58.7 ± 4.2
nM (n = 3) and 53.2 ± 3.5 nM (n = 3). Notably, kb-NB142-
70 and kb-NB184-02 exhibited about 2-fold greater selec-
tivity toward PKD1. In contrast, the compound kb-
NB165-92 was more selective toward PKD3, showing
approximately 2-fold greater inhibition of PKD3 (IC50 =
58.8 ±7.3 nM, n = 3) than PKD1 or -2 (IC50 = 111.2 ± 6.0
and 100.7 ±10.9, n = 3, respectively), which is unique
among the compounds tested. Other compounds, namely
kb-NB165-09 and kb-NB165-31 showed similar inhibi-
tion of all three isoforms. Overall, our results demon-
strated that core structural modification of CID755673
substantially enhanced its potency, but had less effect on
isoform selectivity.
The analogs inhibit PMA-induced endogenous PKD1 
activation
To determine whether the compounds are active in cells,
we tested their ability to inhibit activation of PKD1 by
phorbol 12-myristate 13-acetate (PMA) in LNCaP pros-
tate cancer cells. PKD1 has been shown to be the pre-
dominant isoform expressed in these cells [18], and
stimulation with PMA leads to PKC-dependent phospho-
rylation of Ser738/742 in the activation loop followed by
autophosphorylation of PKD1 on Ser916 in the C-termi-
nus [8,10]. Since catalytic activity of PKD1 correlates well
with the phosphorylation state of Ser916 [10], we mea-
sured both p-Ser916 and p-Ser742 levels by Western blot
analysis to track PKD1 activity. As is shown in Fig. 4 (lane
2), addition of PMA alone induced phosphorylation of
both Ser916 and Ser742 of PKD1. When LNCaP cells were
pretreated with the novel CID755673 analogs before
PMA treatment, concentration-dependent inhibition of
phosphorylation at both Ser916 and Ser742 of PKD1 was
observed (Fig. 4, lanes 3-7). This effect appeared to be
most potent for the compound kb-NB142-70, with a cal-
culated cellular IC50 for inhibition of Ser916 phosphoryla-
tion of 2.2 ± 0.6 μM (n = 3) (Table 2). kb-NB165-09 and
kb-NB165-92 showed similar cellular activity, with IC50s
of 3.1 ± 0.5 (n = 3) and 2.6 ± 0.7 μM (n = 3) respectively.
Consistent with our in vitro data, kb-NB184-02 was again
the least potent compound, demonstrating a cellular IC50
of 18.6 ± 2.0 μM (n = 3). GAPDH was used as a loading
control instead of PKD1 because the PKD1 antibody
showed a slight inconsistency in detecting phosphory-
lated and non-phosphorylated forms of PKD1 (Fig. 4 and
data not shown). Taken together, these results indicated
that the analogs were capable of inhibiting PKD1 in intact
cells.
Specificity of CID755673 and its analogs to PKD
We previously reported that CID755673 showed selectiv-
ity toward PKD and did not inhibit several other kinases
tested, including PLK1, CAK, protein kinase B (AKT/
PKB), PKCα, -βI, -δ, or CAMKIIα. To determine whether
the novel analogs retained this specificity, we tested the
compounds against their ability to inhibit PKCα, -βI, -δ,
and CAMKIIα in in vitro radiometric kinase activity
assays. All analogs were poor inhibitors of PKCα and
PKCβI, with only slight (< 50%) inhibitory activity at 10
μM concentration (Fig. 5A and 5B). This was also true for
PKCδ and CAMKIIα with the exception of kb-NB165-31,
which did show nearly 50% inhibitory activity toward
PKCδ and about 70% inhibition of CAMKIIα activity at
10 μM concentration (Fig. 5C and 5D). As a positive con-
trol, the potent PKC inhibitor GF109203X showed strong
inhibition of all three of these isoforms (Fig. 5A-C).
Table 2: Cellular inhibition of PKD1 autophosphorylation 
at S916 by CID755673 analogs
Compound Cellular IC50 (μM)
kb-NB142-70 2.2 ± 0.6 (n = 3)
kb-NB165-09 3.1 ± 0.5 (n = 3)
kb-NB165-31 8.6 ± 2.0 (n = 3)
kb-NB165-92 2.6 ± 0.7 (n = 2)
kb-NB184-02 18.6 ± 2.0 (n = 3)
Cellular IC50 was determined by densitometry analysis of Western 
blotting data for PKD1 autophosphorylation at S916 in LNCaP 
cells. Each IC50 was calculated as the mean ± S.E.M. of at least two 
independent experiments. *n, number of independent 
experimentsLaValle et al. BMC Chemical Biology 2010, 10:5
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To further investigate the specificity of this series of
compounds, a kinase profiling experiment was conducted
on CID755673, testing 48 additional kinases (Table 3).
CID755673 showed "significant" inhibition (≥ 50%) of six
out of a total 48 kinases - MK2, GSK-3β, CK1δ, MK5/
PRAK, CDK2, and ERK1. As a control, PKD2 activity was
reduced by 95% when treated with 10 μM CID755673. A
separate, smaller scale analysis of the kinase inhibition
profile of the CID755673 analogs has also been con-
ducted and showed similar patterns of inhibition as the
parental compound, indicating that the analogs of
CID75573 act on similar targets (data not shown).
Effects of the CID755673 analogs on tumor cell death, 
proliferation, and cell cycle distribution
Given the effects of PKD3 knockdown by siRNA or
CID755673 in the inhibition of prostate cancer cell prolif-
eration [18,20] and the implications that PKD regulates
cell survival and proliferation [12,29], we wanted to test
whether the new compounds were cytotoxic and whether
they also inhibited prostate cancer cell proliferation.
Therefore, we determined the cytotoxic effects of the
compounds on PC3 cells by MTT assay. As shown in Fig.
6, the parental compound induced very little cell death,
having an EC50 of 319.8 μM in this context. In contrast,
the analogs showed considerable increases in cytotoxic-
ity. kb-NB142-70 was again the most potent, causing con-
siderable cell death and demonstrating an EC50 of 8.025
μM. kb-NB165-09, kb-NB165-31, and kb-NB184-02
showed similar effects on cell death, with EC50s of 49.98
μM, 31.91 μM, and 33.84 μM, respectively.
In addition to the novel analogs demonstrating
increased cytotoxicity when compared to the parental
compound, they also caused dramatic arrest in prostate
cancer cell proliferation when applied at 10 μM concen-
tration to PC3 cells, as determined by cell counts over six
consecutive days (Fig. 7A). In contrast to the parental
compound, which only slowed cell proliferation, the
Figure 5 Selectivity of the CID755673 analogs. Inhibition of PKCα (A), PKCβI (B), PKCδ (C), or CAMKIIα (D) by each of the 5 analogs was determined 
at 100 nM, 1 μM, and 10 μM concentrations. In the PKC assays, the potent PKC inhibitor GF109203X was used as a control. Data are the mean ± S.E.M. 
of three independent experiments. Statistical significance was determined using the unpaired t-test. ns, not statistically significant; *, p < 0.05; **, p < 
0.01; ***, p < 0.001.LaValle et al. BMC Chemical Biology 2010, 10:5
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novel analogs drastically inhibited cell proliferation, with
kb-NB142-70 being most potent among the compounds.
To gain insight into the mechanism of growth inhibi-
tion caused by the analogs, we conducted cell cycle analy-
sis in PC3 cells. Our previous data indicated the parent
compound CID755673 caused G2/M phase cell cycle
arrest when applied at 10 or 25 μM for six days [20]. In
the present study, PC3 cells were treated with 10 μM
compound for 48 h and cell cycle distribution was ana-
lyzed by flow cytometry after propidium iodide labeling
of fixed cells. Indeed, the compounds showed increased
accumulation in the G2/M phase of the cell cycle when
compared to the DMSO treated control or to CID755673
(note that in this experiment, 48 h incubation of
CID755673 was too short to induce G2/M arrest) (Fig.
7B). Taken together, our data indicated that the novel
analogs of CID755673 were potent inhibitors of survival
and proliferation in prostate cancer cells.
CID755673 and its analogs cause accumulation of cyclin D1 
and cyclin D3
Though our evidence supports that CID755673 and its
analogs induce cell cycle arrest at G2/M phase, a recent
study by Torres-Marquez et al. demonstrated that
CID755673 treatment enhanced phorbol ester- and
growth factor-induced DNA synthesis and G1/S cell cycle
progression in Swiss 3T3 cells independent of PKD1 [30].
In this study, it is important to note that both DNA syn-
thesis and cell cycle distribution were determined after 40
h CID755673 treatment, while in our previous study cell
proliferation was measured by counting cell numbers for
six consecutive days of CID755673 treatment [20].
Although it was clear based on counting cell numbers
Table 3: Kinase profiling report for CID755673
CID755673, 10 μM CID755673, 10 μM
Kinase Average % Inhibition Kinase Average % Inhibition
ABL 8 KDR 8
AKT1 3 MAPKAPK2 95
AKT2 4 MARK1 12
AMPK 35 MET 18
AurA 7 MSK1 7
BTK -3 p38a 2
CAMK4 17 p70S6K 44
CDK2 71 PAK2 3
CHK1 7 PDGFRα 5
CHK2 4 PDK1 22
CK1δ 82 PIM2 6
c-Raf 2 PKA 6
EGFR 11 PKCη 40
ErbB4 1 PKCγ 30
Erk1 50 PKCθ 32
Erk2 31 PKCζ -4
FGFR1 16 PKD2 95
FLT3 14 PKG1α 13
GSK3β 86 PKG1β 11
IGF1R -2 MK5/PRAK 75
Ikkb 49 RSK1 29
IBSR 3 SGK1 9
IRAK4 0 SRC 7
JNK2 36 SYK -8
48 kinases were interrogated using a single-dose in vitro kinase assay at 10 μM CID755673. -20 to +20% inhibition, baseline levels; >20 to 49% 
inhibition, compound only marginally actively inhibits the kinase; >50% inhibition, compound is actively inhibiting the kinase. The assay was 
performed by Caliper Life Sciences (Hanover, MD).LaValle et al. BMC Chemical Biology 2010, 10:5
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that CID755673 inhibited cell proliferation and ultimately
caused G2/M arrest, our study did not rule out the possi-
bility that this compound could affect other stages of cell
cycle progression. To investigate this possibility and to
determine if CID755673 indeed affects the G1/S transi-
tion, we measured the levels of cell cycle markers in
response to treatment with CID755673 and its analogs.
As shown in Fig. 8A, CID755673 induced cyclin D1 and
D3 expression in a concentration-dependent manner in
PC3 cells, suggesting a role for CID755673 in promoting
the G1/S transition. Importantly however, the analogs of
CID755673, with the exception of kb-NB165-09, showed
much reduced effects on levels of cyclin D1 or D3, imply-
ing the specificity of these compounds was improved
(Fig. 8B). These data support the idea that CID755673
and its analogs have a complex effect on cell cycle pro-
gression; in addition to the induction of G2/M arrest and
subsequent inhibition of cell proliferation, these com-
pounds may also promote the G1/S transition.
Effects of the CID755673 analogs on tumor cell migration 
and invasion
Previous reports have indicated that PKD may have
important roles in the regulation of cell motility, adhe-
sion, and invasion [31-33]. Additionally, we previously
demonstrated that the PKD inhibitor CID755673 slowed
cell migration and invasion in prostate cancer cells [20].
In order to assess whether the novel analogs of
CID755673 retained the ability to slow prostate cancer
cell migration and invasion, we performed two assays.
First, we evaluated the effects of the compounds on
migration in both DU145 and PC3 cells by wound healing
assay. Confluent cells were wounded and then treated
with either 5 μM or 25 μM inhibitor. Wound closure was
inhibited in a concentration-dependent manner in both
DU145 and PC3 cells (Fig. 9A and 9B). In this assay, kb-
NB142-70 and kb-NB165-09 were the most potent inhib-
itors of wound healing, with wounds showing only 25-
35% closure when treated with 25 μM concentration of
these two compounds. kb-NB165-31 appeared to
strongly resemble the potency of the parental compound,
demonstrating 55-60% wound closure at 25 μM concen-
tration in both PC3 and DU145 cells. The analogs also
significantly inhibited tumor cell invasion measured by
Matrigel invasion assay (Fig. 10A and 10B). Consistent
with our previously reported results, 10 μM CID755673
significantly inhibited invasion of DU145 cells. Invasion
was also inhibited by kb-NB165-31, kb-NB165-92, and
kb-NB184-02 at levels similar to the parental compound.
However, kb-NB142-70 and kb-NB165-09 showed
increased potency in this assay, reducing percent invasion
to only 10%. Taken together, these results support the
conclusion that the novel analogs of CID755673 are
potent inhibitors of prostate cancer cell migration and
invasion.
Discussion
In this study, we report the generation and characteriza-
tion of five novel analogs of the PKD inhibitor
CID755673. This compound, previously identified as a
novel PKD inhibitor, inhibited PKD1 with an IC50 of 182
nM in vitro, and blocked cancer-associated properties of
prostate cancer cells. The novel analogs, synthesized to
have modifications in both the core structure and side
chains, showed equal or increased potency to PKD1 inhi-
bition  in vitro and in cells when compared with
CID755673. Additionally, we confirmed they also inhib-
ited PKD2 and PKD3 in vitro, acting as pan-PKD inhibi-
tors like the parental compound. Of the compounds
reported here, the most potent was kb-NB142-70, which
inhibited PKD1 with nearly a 7-fold greater potency com-
pared to the parental compound. Furthermore, kb-
NB142-70 inhibited PKD2 and PKD3 about 4-fold stron-
ger than CID755673. The analogs also demonstrated
increased inhibition of PMA-induced autophosphoryla-
tion of endogenous PKD1 in LNCaP prostate cancer cells
when compared to the parental compound. Thus, we
have established that these small molecule analogs of
CID755673 are also potent inhibitors of PKD both in
vitro and in cells.
CID755673 is superior in specificity when compared
with other compounds known to inhibit PKD, such as
staurosporine and staurosporine-related the compounds
Figure 6 Cytotoxic effects of the CID755673 analogs in PC3 cells. 
PC3 cells were seeded into 96-well plates (3000 cells/well) and were 
then incubated in media containing 0.3-100 μM inhibitors for 72 h. 
MTT solution was added to each well and incubated for 4 h. Optical 
density was read at 570 nm to determine cell viability. The EC50 was de-
termined as the mean ± S.E.M. of three independent experiments for 
each compound.LaValle et al. BMC Chemical Biology 2010, 10:5
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K252a and Gö6976, even though these compounds have
been reported to inhibit PKD in the low double- and sin-
gle-digit nanomolar range (IC50s of 40 nM, 7 nM, and 20
nM, respectively). A kinase profiling report demonstrated
that CID755673 may also target a few additional kinases,
including glycogen synthase kinase-3β (GSK3β), casein
kinase 1δ (CK1δ), mitogen-activated protein kinase-acti-
vated protein kinase (MK) 5, MK2, and cyclin-dependent
kinase 2 (CDK2). Importantly however, CID755673 lacks
or shows only marginal activity towards almost all PKC
isoforms that have been tested thus far (including PKC-α,
-β, -γ, -δ, -η, -θ and -ζ), which distinguishes it from the
commonly used PKC/PKD inhibitors such as Gö6976.
This feature may allow selective targeting of PKD-medi-
ated signaling pathways and cellular processes, though
discretion must be used since additional targets of
CID755673 do indeed exist. Similar to the parental com-
pound, the novel analogs for the most part retained spec-
ificity when tested against PKCα, -βI, -δ, and CAMKIIα.
One compound, kb-NB165-31, did show significant
inhibitory activity toward PKCδ and CAMKIIα when
tested at 10 μM concentration. This compound has an
iodine atom added as a side chain of the benzene ring in
kb-NB142-70, which retained strong selectivity to PKD in
vitro, suggesting that the increase in lipophilicity and the
introduction of a polarizable group at the phenol ortho-
position reduce compound specificity. Interestingly, in
the case of kb-NB165-92, the expansion of the lactam by
one carbon to a fused 8-membered ring reduced the
Figure 7 Effects of the CID755673 analogs on cell proliferation in PC3 cells. A, The analogs caused potent arrest in cell proliferation. PC3 cells 
were plated in triplicate in 24-well plates. Cells were allowed to attach overnight. A cell count at day 1 was made, and then either vehicle (DMSO) or 
the indicated compound at 10 μM concentration was added. Cells were counted daily for a total of 6 days. Media and inhibitor were refreshed every 
2 days. The mean cell number ± S.E. was plotted over time. The experiment was repeated twice and a representative graph is shown. Statistical sig-
nificance versus Day 1 cell count was determined by unpaired t-test and is indicated. *, p < 0.05; **, p < 0.01; ***, p < 0.001. B, The analogs caused G2/
M phase cell cycle arrest. PC3 cells were treated with either vehicle (DMSO), or 10 μM concentration of indicated compound for 48 hours. Cell cycle 
distribution was determined by flow cytometry after propidium iodide labeling of fixed cells. The experiment was repeated three times and a repre-
sentative is shown for each compound.LaValle et al. BMC Chemical Biology 2010, 10:5
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potencies for PKD1 and PKD2 by 2-4 fold, while not
altering potency for PKD3, implying that zone III of our
pharmacophore may contain determinants for isoform-
selectivity. However, this concept should be further
exploited as methoxy analogs of kb-NB142-70 and kb-
NB165-92, in contrast, did not exhibit an analogous shift
in isoform-selectivity.
Cellular activity of the analogs was demonstrated
through inhibition of PMA-induced activation of endoge-
nous PKD1 by measuring the phosphorylation levels of
Ser916  and Ser742. Based on the canonical pathway of
PKC-dependent PKD activation, phorbol ester-stimu-
lated phosphorylation on Ser738/742 by PKC followed by
autophosphorylation of PKD1 on Ser916 would result in
full activation of PKD [8,10,34,35]. However, recent stud-
ies suggest that Ser742 may be a site of both trans- and
autophosphorylation. While initial, early catalytic activa-
tion of PKD requires rapid transphosphorylation on
Ser738/742  by PKC isoenzymes, the major mechanism
required to maintain prolonged PKD activation is Ser742
autophosphorylation [11]. Therefore, the observed dose-
dependent inhibition of Ser742 phosphorylation on PKD1
after agonist stimulation (100 nM PMA for 20 min) by
our novel analogs reflects the inhibition of PKD1 auto-
phosphorylation at this site, analogous to the inhibition
of Ser916 phosphorylation. Further analysis is required to
determine the precise mechanism of inhibition of PKD by
these novel compounds.
PKD has been implicated in the regulation of cell prolif-
eration, survival, and apoptotic pathways in multiple cell
types [16,18,36]. We have previously shown that PC3 cells
predominantly express high levels of PKD3, potentially
making them very sensitive to PKD3 inhibition, and that
knockdown of PKD3 by siRNA causes strong arrest in cell
proliferation in these cells [18]. Here, we have shown that
one of the more striking differences between the parental
compound and its analogs is the increase in cytotoxicity
and dramatic arrest in cell proliferation. While
CID755673 is only minimally cytotoxic to prostate cancer
cells, and can be tolerated at high concentrations for pro-
longed treatments [20], the novel analogs induced signifi-
cant cytotoxicity in PC3 cells after much shorter
treatments (48 h) and at much lower concentrations (5-10
μM). Based on our preliminary analysis, the effects of the
compounds on viability in other prostate cancer cells
(LNCaP and DU145) are comparable to those in PC3 cells
(data not shown). The inhibitors appear to exhibit a gen-
eral inhibitory effect on cell viability, with potency vary-
ing between different tumor cell types. Additionally, the
analogs cause much more potent arrest in cell prolifera-
tion than the parental compound. Since the anti-prolifer-
ative effects of the analogs phenocopied those caused by
knockdown of PKD3 in PC3 cells, it is conceivable that
these effects, at least to some extent, are mediated
through inhibition of PKD. That said, we cannot exclude
the possibility that CID755673 and its analogs have addi-
tional cellular targets whose inhibition may contribute to
the elevated cytotoxicity and potent growth arrest
observed in prostate cancer cells. Moreover, since the
analogs, mimicking the parental compound, all induced
apparent G2/M cell cycle arrest, it is likely that the mech-
anisms underlying the growth inhibition caused by the
analogs are similar to those induced by the parental com-
pound. Based on the kinase profiling data, we speculate
that, in addition to PKD, the inhibitory effect of
CID755673 and its analogs on cell proliferation may be
contributed to the inhibition of CDK2, another potential
target of CID755673. Although CDK2 is generally consid-
ered a regulator of S-phase entry [37,38], some reports
have also linked it to the G2/M transition [38,39]. Accord-
ing to the accepted model of cell cycle progression, CDK2
is activated by binding to cyclin E in late G1 phase, result-
ing in phosphorylation of the retinoblastoma protein (Rb)
and facilitating the G1/S-phase transition [40]. It also pro-
Figure 8 CID755673 and its analogs cause accumulation of cyclin 
D1 and cyclin D3. A, PC3 cells were treated with increasing concentra-
tions of CID755673 for 48 hrs. Inhibitor and growth media were re-
freshed after 24 hrs. Western blots for cyclin D1 and cyclin D3 are 
shown. B, PC3 cells were treated with 25 μM CID755673, 10 μM kb-
NB142-70, 10 μM kb-NB165-09, 1 μM kb-NB165-92, or 10 μM kb-NB184-
02 for 48 hrs. Note that 1 μM kb-NB165-92 was used in this assay since 
this compound at 10 μM caused significant cell death. Inhibitors and 
growth media were refreshed after 24 hrs. Western blots for cyclin D1 
and D3 are shown. GAPDH was used as a loading control.
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motes progression of S-phase by binding to cyclin A.
However, it has been reported that inhibition of CDK2 by
expression of a dominant negative CDK2 mutant or over-
expression of p27kip1 can cause accumulation in G2/M
[38,39]. Therefore, it is plausible that the G2/M arrest and
reduced cell proliferation caused by CID755673 and its
analogs is in part due to inhibition of CDK2. It is also pos-
sible that CID755673 and its analogs may inhibit other
members of the CDK family, for example CDK1, which
plays a critical role in G2/M cell cycle progression. Finally,
it must be stated that although CKD2 and a few other
proteins were identified as potential hits in a single dose
kinase profiling experiment, the activities of CID755673
and its analogs toward these targets need to be further
validated in 10-point dose-response kinase assays.
Although CID755673 and its analogs potently inhibited
cell proliferation, their effects on cell cycle progression
appeared to complex, involving two opposing effects on
different stages of the cell cycle: 1) promotion of the G1/S
transition; 2) induction of G2/M arrest. The G2/M arrest
ultimately leads to cessation of cell proliferation. Our
findings that CID755673 and its analogs induced cyclin
D1 and D3 expression may underlie the potentiation
effect of CID755673 on the G1/S transition induced by
other mitogens [30]. Given that the report by Torres-
Marquez et al. used DNA synthesis and cell cycle distri-
bution as readouts, it r emains t o be det ermined if the
potentiation effect reported indeed resulted in increased
cell number (cell proliferation) since the G2/M block may
ultimately inhibit this effect. With regard to the potential
targets that may account for this effect, we hypothesize,
based on our kinase profiling data, that GSK-3β could
play a role since active GSK-3β has a negative effect on
cell cycle progression [41]. Expression of the cell cycle
proteins cyclin D1 and cyclin D3 is regulated by GSK-3β
signaling at the transcriptional level and through protein
degradation [41-43]. Thus, inhibition of GSK-3β may be
in part responsible for the promotion of the G1/S transi-
tion and the reported potentiation effect with other mito-
gens. It is important to note that the analogs of
CID755673 in general showed less activity in inducing
cyclin D1 or D3 expression, suggesting that they are less
active at promoting the G1/S transition and are more
selective for PKD. This correlated to their much
enhanced growth suppressive and cytotoxic effects in
prostate cancer cells, implying that reducing/removing
the G1/S cell cycle-promoting effect of the analogs could
significantly improve the antitumor activity of these ana-
logs.
In addition to the effects of these analogs on cell sur-
vival and proliferation, we also show that they are potent
inhibitors of prostate cancer cell migration and invasion.
kb-NB142-70 and kb-NB165-09 in particular, strongly
reduced wound healing in both DU145 cells and PC3 cells
in a dose-dependent manner, and significantly inhibited
invasion of DU145 cells through Matrigel invasion inserts
when applied at 10 μM concentration. Furthermore, the
pattern of inhibition exhibited by the analogs is fairly
Figure 9 Effects of the CID755673 analogs on prostate cancer cell migration. The analogs inhibited wound healing in prostate cancer cells. 
DU145 cells (A) or PC3 cells (B) were grown to confluence in 6-well plates. The monolayer was wounded and imaged immediately. Cells were then 
treated with either vehicle (DMSO) or analogs at indicated concentration for 24 hours. Cells were then fixed and stained with 0.5% crystal violet. Per-
centage wound closure was calculated as an average of 9 determinations for each concentration/compound as described under "Methods." Data 
shown are the mean ± S.E.M. for three independent experiments. Statistical significance versus the DMSO control was determined by unpaired t-test 
in GraphPad Prism V. ns, not statistically significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001.LaValle et al. BMC Chemical Biology 2010, 10:5
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consistent with their inhibitory activities toward PKD.
This suggests an important role for PKD in prostate can-
cer cell motility and supports the potential value of thera-
peutic targeting of PKD in the reduction or prevention of
prostate tumor metastases. Though the mechanism
through which PKD may mediate migration and invasion
is not yet known, several recent reports have begun to
shed light onto the complexity of these signaling path-
ways, suggesting PKD involvement in both β-catenin and
Akt signaling in prostate cancer cells [18,19,32].
Conclusions
In conclusion, we report the biochemical and functional
analysis of several novel analogs of the PKD inhibitor
CID755673. These analogs show equal and increased
potency toward PKD inhibition both in vitro and in cells.
The new lead compounds display prominent cytotoxic
and anti-proliferative effects, and potently inhibit migra-
tion and invasion in prostate cancer cells. Although the
molecular mechanisms underlying some of the biological
effects of these compounds appear to be complex and
may involve additional targets, their potent effects on
multiple cancer-associated biologies warrant further
development of this series of compounds toward possible
clinical application in cancer therapy.
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is the mean ± S.E.M. of two independent experiments. Statistical significance versus the control DMSO was determined by unpaired t-test. ***, p < 
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